TSC2 and tuberous sclerosis: As the TSC is a key negative regulator of the mTORC1 signaling pathway, loss-of-function mutations in TSC1 or TSC2 lead to the development of various cancers, as well as the tuberous sclerosis complex, characterized by hamartoma formation in multiple tissues (Henske et al, 2016).